Lee Richard Sean, Sad Kirti, Fawwal Dorelle V, Spangle Jennifer Marie
Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Biology, Emory College, Atlanta, GA 30322, USA.
Cancers (Basel). 2023 Aug 7;15(15):4005. doi: 10.3390/cancers15154005.
Breast cancer pathogenesis, treatment, and patient outcomes are shaped by tumor-intrinsic genomic alterations that divide breast tumors into molecular subtypes. These molecular subtypes often dictate viable therapeutic interventions and, ultimately, patient outcomes. However, heterogeneity in therapeutic response may be a result of underlying epigenetic features that may further stratify breast cancer patient outcomes. In this review, we examine non-genetic mechanisms that drive functional changes to chromatin in breast cancer to contribute to cell and tumor fitness and highlight how epigenetic activity may inform the therapeutic response. We conclude by providing perspectives on the future of therapeutic targeting of epigenetic enzymes, an approach that holds untapped potential to improve breast cancer patient outcomes.
乳腺癌的发病机制、治疗方法及患者预后受肿瘤内在基因组改变的影响，这些改变将乳腺肿瘤分为不同的分子亚型。这些分子亚型通常决定了可行的治疗干预措施，并最终决定患者的预后。然而，治疗反应的异质性可能是潜在表观遗传特征的结果，这些特征可能进一步细化乳腺癌患者的预后。在本综述中，我们研究了驱动乳腺癌染色质功能变化以促进细胞和肿瘤适应性的非遗传机制，并强调表观遗传活性如何为治疗反应提供信息。我们通过对表观遗传酶治疗靶点的未来前景提供观点来结束本文，这种方法具有改善乳腺癌患者预后的未开发潜力。
